Lymph Node Metastases Diagnosed by 18F-FDG-PET/CT in Esophageal Squamous Cell Cancer Treated With Concurrent Chemoradiotherapy

Background/Aim: To evaluate whether factors related to the clinical staging of lymph node (LN) metastasis diagnosed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (PET/CT) correspond to poor survival in esophageal squamous cell cancer (ESCC) patients treated with concurre...

Full description

Saved in:
Bibliographic Details
Published in:Anticancer research 2019-09, Vol.39 (9), p.4977
Main Authors: Ogino, Ichiro, Watanabe, Shigenobu, Misumi, Toshihiro, Hata, Masaharu, Kunisaki, Chikara
Format: Article
Language:English
Subjects:
Abdomen
Body mass
Body mass index
Body size
Cancer
Cell survival
Chemoradiotherapy
Chemotherapy
Computed tomography
Esophagus
Fluorine isotopes
Impact analysis
Lymph nodes
Lymphatic system
Metastases
Metastasis
Multivariate analysis
Patients
Positron emission
Positron emission tomography
Radiation therapy
Survival
Tomography
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aim: To evaluate whether factors related to the clinical staging of lymph node (LN) metastasis diagnosed by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (PET/CT) correspond to poor survival in esophageal squamous cell cancer (ESCC) patients treated with concurrent chemoradiotherapy (CCRT). Patients and Methods: A total of 69 patients with curative intent and no prior treatment for ESCC or simultaneous treatment for synchronous cancers were investigated. A maximum standardized uptake value (SUVmax) on the highest image pixel in the LN ≥2.5 was considered positive. Location of the involved LN and its impact on survival were analyzed. Results: In the univariate analysis of location, metastasis of the abdominal site, regional abdominal LN, and left gastric LN station negatively affected overall survival (OS) and disease-free survival (DFS). Other adverse clinical factors influencing OS included T4, clinical stage IVA and body mass index
ISSN:0250-7005
1791-7530
DOI:10.21873/anticanres.13687